BR0315795A - Pró-medicamentos de monofosfato de citarabina - Google Patents

Pró-medicamentos de monofosfato de citarabina

Info

Publication number
BR0315795A
BR0315795A BR0315795-4A BR0315795A BR0315795A BR 0315795 A BR0315795 A BR 0315795A BR 0315795 A BR0315795 A BR 0315795A BR 0315795 A BR0315795 A BR 0315795A
Authority
BR
Brazil
Prior art keywords
cytarabine
monophosphate prodrugs
cytarabine monophosphate
prodrugs
pyridyl
Prior art date
Application number
BR0315795-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Serge H Boyer
Mark D Erion
Original Assignee
Metabasis Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabasis Therapeutics Inc filed Critical Metabasis Therapeutics Inc
Publication of BR0315795A publication Critical patent/BR0315795A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6571—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and oxygen atoms as the only ring hetero atoms
    • C07F9/6574—Esters of oxyacids of phosphorus
    • C07F9/65742—Esters of oxyacids of phosphorus non-condensed with carbocyclic rings or heterocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
BR0315795-4A 2002-10-31 2003-10-31 Pró-medicamentos de monofosfato de citarabina BR0315795A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US42321102P 2002-10-31 2002-10-31
US42325902P 2002-10-31 2002-10-31
PCT/US2003/034690 WO2004041837A1 (en) 2002-10-31 2003-10-31 Novel cytarabine monophosphate prodrugs

Publications (1)

Publication Number Publication Date
BR0315795A true BR0315795A (pt) 2005-09-13

Family

ID=32314479

Family Applications (2)

Application Number Title Priority Date Filing Date
BR0315795-4A BR0315795A (pt) 2002-10-31 2003-10-31 Pró-medicamentos de monofosfato de citarabina
BR0315806-3A BR0315806A (pt) 2002-10-31 2003-10-31 Fosfato diésteres cìclicos de 1,3-propano-1-aril diós e seu uso na preparação de pró-drogas

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR0315806-3A BR0315806A (pt) 2002-10-31 2003-10-31 Fosfato diésteres cìclicos de 1,3-propano-1-aril diós e seu uso na preparação de pró-drogas

Country Status (13)

Country Link
US (4) US7151092B2 (2)
EP (2) EP1556398B1 (2)
JP (2) JP4689274B2 (2)
KR (2) KR101115210B1 (2)
AT (1) ATE442375T1 (2)
AU (2) AU2003286816B2 (2)
BR (2) BR0315795A (2)
CA (2) CA2503729C (2)
DE (1) DE60329211D1 (2)
IL (2) IL167984A (2)
MX (2) MXPA05004503A (2)
PL (2) PL212929B1 (2)
WO (2) WO2004041837A1 (2)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
EP2223927B1 (en) * 2002-05-13 2014-10-15 Metabasis Therapeutics, Inc. Salts of a phosphonic acid based prodrug of PMEA
WO2003095665A2 (en) * 2002-05-13 2003-11-20 Metabasis Therapeutics, Inc. Pmea and pmpa cyclic producing synthesis
BR0315795A (pt) 2002-10-31 2005-09-13 Metabasis Therapeutics Inc Pró-medicamentos de monofosfato de citarabina
US20050182252A1 (en) * 2004-02-13 2005-08-18 Reddy K. R. Novel 2'-C-methyl nucleoside derivatives
CA2565966A1 (en) * 2004-06-08 2005-12-29 Metabasis Therapeutics, Inc. Lewis acid mediated synthesis of cyclic esters
WO2007022073A2 (en) * 2005-08-12 2007-02-22 Merck & Co., Inc. Novel 2'-c-methyl and 4'-c-methyl nucleoside derivatives
US20070241502A1 (en) * 2006-04-14 2007-10-18 Campbell Darrell C Poker game and apparatus for play thereof
US7584968B2 (en) * 2006-04-14 2009-09-08 Seven Generations, Inc. Poker game and apparatus for play thereof
AR069740A1 (es) * 2007-11-29 2010-02-17 Metabasis Therapeutics Inc Compuestos nucleosidos antivirales
BRPI0821106A2 (pt) * 2007-11-29 2015-06-16 Ligand Pharm Inc Pró-fármacos de nucleosídeo e usos dos mesmos
EP2279011B1 (en) 2008-04-30 2017-10-25 Siemens Medical Solutions USA, Inc. Substrate based pet imaging agents
CN101787064B (zh) * 2009-01-23 2013-03-13 高峰 阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途
JP5631414B2 (ja) * 2010-01-15 2014-11-26 ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ ホスホ置換アルコキシアミン化合物
WO2011113174A1 (zh) * 2010-03-15 2011-09-22 Gao Feng 阿糖胞苷衍生物及其在抗癌抗肿瘤中的用途
RU2732440C2 (ru) * 2013-06-24 2020-09-16 Кэнбас Ко., Лтд. Пептиды и пептидомиметики для комбинированного применения и лечения в субпопуляциях пациентов с раковыми заболеваниями
GB201317166D0 (en) * 2013-09-27 2013-11-06 Astex Therapeutics Ltd Pharmaceutical compounds
AU2015217221A1 (en) 2014-02-13 2016-08-11 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
CN106687118A (zh) 2014-07-02 2017-05-17 配体药物公司 前药化合物及其用途
AU2016301188A1 (en) 2015-08-06 2018-02-15 Chimerix, Inc. Pyrrolopyrimidine nucleosides and analogs thereof useful as antiviral agents
US11058701B2 (en) 2015-12-03 2021-07-13 Biosight Ltd. Cytarabine conjugates for cancer therapy
US12071450B2 (en) 2015-12-03 2024-08-27 Biosight Ltd. Salts of conjugates for cancer therapy
AU2016362239B2 (en) * 2015-12-03 2021-03-25 BioCytara Ltd. Salts of conjugates for cancer therapy
US12064445B2 (en) 2015-12-03 2024-08-20 Biosight Ltd. Cytarabine conjugates for cancer therapy
JP6775591B2 (ja) * 2016-09-20 2020-10-28 株式会社島津製作所 両親媒性ブロックポリマーを用いた薬剤内包分子集合体
ES3011607T3 (en) 2017-09-21 2025-04-07 Chimerix Inc Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7h-pyrrolo(2,3-d)pyrimidine-5-carboxamide and uses thereof
CN109956985A (zh) * 2017-12-22 2019-07-02 浙江柏拉阿图医药科技有限公司 肝递送阿糖胞苷前体药物核苷环磷酸酯化合物及应用
CA3087932A1 (en) 2018-01-09 2019-07-18 Ligand Pharmaceuticals, Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL222157A (2) * 1956-12-20
US3116282A (en) * 1960-04-27 1963-12-31 Upjohn Co Pyrimidine nucleosides and process
US3328388A (en) 1964-09-02 1967-06-27 Merck & Co Inc Arabinofuranosyl pyrimidines and methods of preparing same
US4440740A (en) * 1982-04-26 1984-04-03 Merck & Co., Inc. α-Keto aldehydes as enhancing agents of gastro-intestinal drug absorption
US4579849A (en) 1984-04-06 1986-04-01 Merck & Co., Inc. N-alkylguanine acyclonucleosides as antiviral agents
FR2562543B1 (fr) * 1984-04-10 1987-09-25 Elf Aquitaine Nouveaux phosphonites cycliques, leur preparation et applications
US4749694A (en) * 1984-04-26 1988-06-07 Merck & Co., Inc. Novel lysine esters used as absorption
US4537772A (en) * 1984-05-02 1985-08-27 Merck & Co., Inc. Enhancing absorption of drugs from gastrointestinal tract using acylcarnitines
NL8403224A (nl) 1984-10-24 1986-05-16 Oce Andeno Bv Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen.
US4729989A (en) * 1985-06-28 1988-03-08 Merck & Co., Inc. Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts
US4822773A (en) * 1985-06-28 1989-04-18 Merck & Co., Inc. Enhancement of absorption of drugs from gastrointestinal tract using choline ester salts
US4973579A (en) * 1985-06-28 1990-11-27 Merck & Co., Inc. Enhancment of absorption of drugs from gastrointestinal tract using choline ester salts
US4731360A (en) * 1985-08-16 1988-03-15 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
US4692441A (en) * 1985-08-16 1987-09-08 Merck & Co., Inc. Chorine esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
US4847298A (en) * 1985-08-16 1989-07-11 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
US4963525A (en) * 1985-08-16 1990-10-16 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
US4963556A (en) * 1985-08-16 1990-10-16 Merck & Co., Inc. Choline esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
US5159067A (en) * 1987-01-28 1992-10-27 University Of Georgia Research Foundation Inc. 5'-Diphosphohexose nucleoside pharmaceutical compositions
US5077280A (en) * 1988-04-12 1991-12-31 Brown University Research Foundation Treatment of viral infections
EP0338372A3 (en) 1988-04-22 1991-10-09 American Cyanamid Company Solubilized pro-drugs
CA1334752C (en) 1988-08-02 1995-03-14 Ryozo Sakoda Drug effect-enhancing agent for antitumor drug
US5658889A (en) * 1989-01-24 1997-08-19 Gensia Pharmaceuticals, Inc. Method and compounds for aica riboside delivery and for lowering blood glucose
US5118672A (en) * 1989-07-10 1992-06-02 University Of Georgia Research Foundation 5'-diphosphohexose nucleoside pharmaceutical compositions
EP0533833B1 (en) 1990-06-13 1995-12-20 GLAZIER, Arnold Phosphorous produgs
EP0481214B1 (en) * 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
WO1993016388A1 (en) * 1992-02-13 1993-08-19 The Uab Research Foundation Method of detecting and monitoring levels of 3'-amino-3'-deoxythymidine in body fluids and antibodies for same
GB2266527A (en) 1992-03-17 1993-11-03 Merck & Co Inc Substituted azetidinones useful in the treatment of leukemia
GB2266525A (en) 1992-03-17 1993-11-03 Merck & Co Inc Substituted cephalosporin sulfone compositions useful in the treatment of leukemia
AU685128B2 (en) 1993-05-21 1998-01-15 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The New procedure to block the replication of reverse transcriptase dependent viruses by the use of inhibitors of deoxynucleotides synthesis
ATE199906T1 (de) * 1993-06-29 2001-04-15 Mitsubishi Chem Corp Phosphonat-nukleotid ester-derivate
US5567689A (en) * 1993-08-13 1996-10-22 The Uab Research Foundation Methods for increasing uridine levels with L-nucleosides
CA2171550C (en) * 1993-09-10 2008-08-26 Raymond F. Schinazi Nucleosides with anti-hepatitis b virus activity
FR2709754B1 (fr) 1993-09-10 1995-12-01 Centre Nat Rech Scient Composés 2' ou 3'-déoxy- et 2', 3'-didéoxy-beta-L-pentofuranonucléosides, procédé de préparation et application thérapeutique, notamment anti-virale.
US20020120130A1 (en) * 1993-09-10 2002-08-29 Gilles Gosselin 2' or 3' -deoxy and 2', 3' -dideoxy-beta-L-pentofuranonucleo-side compounds, method of preparation and application in therapy, especially as anti- viral agents
EP0719273B1 (en) 1993-09-17 2010-11-03 Gilead Sciences, Inc. Nucleotide analogs
US5437772A (en) 1993-11-01 1995-08-01 The Electrosynthesis Co., Inc. Portable lead detector
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
DE69520360T2 (de) 1994-07-04 2001-08-09 Takeda Chemical Industries, Ltd. Phosphonsäure verbindungen imre herstellung und verwendung
US5665713A (en) * 1995-04-12 1997-09-09 Procter & Gamble Company Pharmaceutical composition for inhibiting the growth of viruses and cancers
PT831852E (pt) * 1995-06-07 2007-02-28 Uab Research Foundation Nucleósidos com actividade anti-vírus da hepatite b
ATE253920T1 (de) 1995-07-17 2003-11-15 Cephalon Inc Phosphor enthaltende hemmer von cystein- und serin-proteasen
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
RU2111970C1 (ru) 1996-06-25 1998-05-27 Иван Игоревич Федоров 3'-оксимино-2',3'-дидезоксинуклеозиды
US6177404B1 (en) * 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
US5948750A (en) * 1996-10-30 1999-09-07 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
DE69819311T2 (de) * 1997-03-07 2004-07-29 Metabasis Therapeutics Inc., San Diego Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase
US6284748B1 (en) * 1997-03-07 2001-09-04 Metabasis Therapeutics, Inc. Purine inhibitors of fructose 1,6-bisphosphatase
US6054587A (en) * 1997-03-07 2000-04-25 Metabasis Therapeutics, Inc. Indole and azaindole inhibitors of fructose-1,6-bisphosphatase
US6130504A (en) * 1997-07-11 2000-10-10 Sharp Kabushiki Kaisha Plasma addressing display device and method for producing the same
US6391305B1 (en) * 1997-09-10 2002-05-21 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US20020115596A1 (en) * 1997-10-27 2002-08-22 Merk & Co., Inc. Conjugates useful in the treatment of prostate cancer
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
CA2322487C (en) * 1998-03-06 2010-07-20 Metabasis Therapeutics, Inc. Novel prodrugs for phosphorus-containing compounds
CA2335617C (en) * 1998-06-24 2009-12-15 Novirio Pharmaceuticals Limited Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
IT1305313B1 (it) * 1998-07-17 2001-05-04 Colla Paolo 3,4 - diidro- 6- benzil-4-oxopirimidine sostituite e relativo processodi produzione e impiego nella terapia delle infezioni da hiv-1.
US6444652B1 (en) * 1998-08-10 2002-09-03 Novirio Pharmaceuticals Limited β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
PT2415776T (pt) * 1998-08-10 2016-07-07 Novartis Ag Beta-l-2'-desoxi-nucleosidos para o tratamento da hepatite b
KR100818845B1 (ko) * 1998-09-09 2008-04-01 메타베이시스 테라퓨틱스, 인크. 신규한 프럭토스 1,6-비스포스파타제의 헤테로방향족 억제제
WO2000026225A2 (en) * 1998-11-05 2000-05-11 Centre National De La Recherche Scientifique Nucleosides with anti-hepatitis b virus activity
US6407077B1 (en) * 1998-11-05 2002-06-18 Emory University β-L nucleosides for the treatment of HIV infection
MXPA01008937A (es) 1999-03-05 2004-04-05 Metabasis Therapeutics Inc Nuevos profarmacos que contienen fosforo.
AU7361400A (en) * 1999-09-08 2001-04-10 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
AU3653301A (en) * 2000-01-28 2001-08-07 Merck & Co., Inc. Treatment or prevention of prostate cancer with a cox-2 selective inhibiting drug
JP2003522790A (ja) * 2000-02-17 2003-07-29 メルク エンド カムパニー インコーポレーテッド Ｃｏｘ−２選択的阻害薬を用いた前立腺癌の治療または予防
MY164523A (en) 2000-05-23 2017-12-29 Univ Degli Studi Cagliari Methods and compositions for treating hepatitis c virus
EA005890B1 (ru) * 2000-05-26 2005-06-30 Айденикс (Кайман) Лимитед СПОСОБЫ ЛЕЧЕНИЯ ИНФЕКЦИЙ, ВЫЗЫВАЕМЫХ ВИРУСОМ ГЕПАТИТА ДЕЛЬТА, С ИСПОЛЬЗОВАНИЕМ β-L-2'-ДЕЗОКСИНУКЛЕОЗИДОВ
EP1736478B1 (en) 2000-05-26 2015-07-22 IDENIX Pharmaceuticals, Inc. Methods and compositions for treating flaviviruses and pestiviruses
US6875751B2 (en) * 2000-06-15 2005-04-05 Idenix Pharmaceuticals, Inc. 3′-prodrugs of 2′-deoxy-β-L-nucleosides
WO2002040021A2 (en) * 2000-11-17 2002-05-23 Idenix (Cayman) Limited Methods for inhibiting the transmission of hiv using topically applied substituted 6-benzyl-4-oxopyrimidines
SK286630B6 (sk) * 2001-01-22 2009-02-05 Merck & Co., Inc. Nukleozidové deriváty, farmaceutický prostriedok s ich obsahom a ich použitie
US6710068B2 (en) * 2001-04-11 2004-03-23 Idenix Pharmaceuticals, Inc. Phenylindoles for the treatment of HIV
US20030232760A1 (en) * 2001-09-21 2003-12-18 Merck & Co., Inc. Conjugates useful in the treatment of prostate cancer
US20040006002A1 (en) * 2001-09-28 2004-01-08 Jean-Pierre Sommadossi Methods and compositions for treating flaviviruses and pestiviruses using 4'-modified nucleoside
EP1435974A4 (en) * 2001-09-28 2006-09-06 Idenix Cayman Ltd METHODS AND COMPOSITIONS FOR THE TREATMENT OF HEPATITIS C VIRUS USING 4 'MODIFIED NUCLEOSIDES
EP2223927B1 (en) * 2002-05-13 2014-10-15 Metabasis Therapeutics, Inc. Salts of a phosphonic acid based prodrug of PMEA
WO2003095665A2 (en) * 2002-05-13 2003-11-20 Metabasis Therapeutics, Inc. Pmea and pmpa cyclic producing synthesis
TW200500375A (en) 2002-06-28 2005-01-01 Idenix Cayman Ltd Modified 2' and 3'-nucleoside prodrugs for treating flaviviridae
PL374792A1 (en) 2002-06-28 2005-10-31 Idenix (Cayman) Limited 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
CN1678326A (zh) 2002-06-28 2005-10-05 埃迪尼克斯(开曼)有限公司 用于治疗黄病毒感染的2'－c－甲基－3'－o－l－缬氨酸酯核糖呋喃基胞苷
BR0315795A (pt) * 2002-10-31 2005-09-13 Metabasis Therapeutics Inc Pró-medicamentos de monofosfato de citarabina

Also Published As

Publication number Publication date
JP5046219B2 (ja) 2012-10-10
JP2006504791A (ja) 2006-02-09
WO2004041834A2 (en) 2004-05-21
IL167990A (en) 2010-12-30
WO2004041834A3 (en) 2004-07-01
US7151092B2 (en) 2006-12-19
PL376327A1 (en) 2005-12-27
KR20050083879A (ko) 2005-08-26
AU2003287389A1 (en) 2004-06-07
IL167984A (en) 2011-09-27
CA2503729C (en) 2012-09-18
US20070021388A1 (en) 2007-01-25
KR101026294B1 (ko) 2011-03-31
ATE442375T1 (de) 2009-09-15
JP4689274B2 (ja) 2011-05-25
US20070037774A1 (en) 2007-02-15
KR20050072776A (ko) 2005-07-12
CA2503730C (en) 2011-10-18
BR0315806A (pt) 2005-09-13
US20040192651A1 (en) 2004-09-30
US20040092476A1 (en) 2004-05-13
AU2003287389B2 (en) 2010-08-12
EP1556393A2 (en) 2005-07-27
US7148349B2 (en) 2006-12-12
EP1556393B1 (en) 2013-12-25
MXPA05004504A (es) 2005-08-16
PL376474A1 (en) 2005-12-27
CA2503729A1 (en) 2004-05-21
EP1556398B1 (en) 2009-09-09
EP1556398A1 (en) 2005-07-27
PL212929B1 (pl) 2012-12-31
WO2004041837A1 (en) 2004-05-21
US7553826B2 (en) 2009-06-30
KR101115210B1 (ko) 2012-04-12
AU2003286816A1 (en) 2004-06-07
CA2503730A1 (en) 2004-05-21
JP2006507308A (ja) 2006-03-02
US7498320B2 (en) 2009-03-03
AU2003286816B2 (en) 2010-08-19
MXPA05004503A (es) 2005-08-16
DE60329211D1 (de) 2009-10-22

Similar Documents

Publication Publication Date Title
BR0315795A (pt) Pró-medicamentos de monofosfato de citarabina
PT1585739E (pt) Arilciclopropilacetamidas substitu?das como activadores da glucocinase
AP2002002637A0 (en) Novel piperazine
NO20026196D0 (no) Kinazolinditosylatsalt forbindelser
EP1501507A4 (en) TETRAHYDROPYRANYL CYCLOPENTYL TETRAHYDROPYRIDOPYRIDINE MODULATORS OF CHEMOKIN RECEPTOR ACTIVITY
MXPA05013752A (es) Procedimiento e intermediarios para la preparacion de (1r,2s,5s)-6,6-dimetil-3-azabiciclo[3,1,0]exan-2-carboxilatos o sales de los mismos.
MXPA02003977A (es) Inhibidores de adhesion de celula mediada por al°2.
PT1299409E (pt) Compostos organicos
ATE314383T1 (de) 2-amino-propanol derivate
IL190905A0 (en) 4-alkoxy cyclohexane-1-amino carboxylic acids and processes for their prepatation
ATE233274T1 (de) Oxyiminopregnancarbolactone
MXPA02010627A (es) Derivados de 2-acil-indol y su uso como farmaco antitumoral.
SE9802206D0 (sv) Novel compounds
ATE466866T1 (de) Synthetisches oligomannosid, seine herstellung und verwendung
MXPA03010766A (es) Nuevos compuestos y composiciones como inhibicores de las catepsinas.
MXPA03001081A (es) Medicamento anti-inflamatorio.
DE69903053D1 (de) Diaminocyclobuten-3,4-dionderivate, deren herstellung und deren verwendung
DK1204658T3 (da) Benzofurylpiperazin-serotoninagonister
DK1056754T3 (da) Phosphatderivater af diaryl-1,3,4-oxadiazolon
TR200102334T2 (tr) Matris metaloproteinazların önleyicileri olarak pirimidin-2,4,6-trionlar.
BRPI0411664A (pt) composição oral antiplaca aquosa estável
DE60107832D1 (en) Chromenylmethylpyrimidindiamine als antibakterielle wirkstoffe
PT1292303E (pt) Formulacao farmaceutica estavel compreendendo modificacao de torsemida ii
AP2002002595A0 (en) Heterocyclic amide derivatives.
ATE213236T1 (de) Substituierte benzyloxyimino-verbindungen

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.